Cannabinoid Receptor 2 (CB2) is a type of protein found on the surface of cells in the immune system and some other tissues. It is one of two known cannabinoid receptors, the other being Cannabinoid Receptor 1 (CB1). Unlike CB1, CB2 is primarily found outside of the brain, in tissues such as the immune system, gastrointestinal tract, and peripheral nervous system.
CB2 receptors are activated by naturally occurring cannabinoids in the body, called endocannabinoids, as well as by cannabinoids found in the cannabis plant, such as CBD. When CB2 receptors are activated, they can modulate immune system function and reduce inflammation.
In medicine, CB2 receptors are of interest due to their potential therapeutic applications in conditions involving inflammation and immune system dysfunction. Researchers have identified a range of conditions that may be impacted by CB2 activation, including pain, multiple sclerosis, inflammatory bowel disease, and rheumatoid arthritis.
CB2 activation has been shown to reduce inflammation in animal models and in human studies. It may also have a role in regulating the immune system and reducing the severity of autoimmune diseases.
CB2 receptor agonists, which are compounds that activate CB2 receptors, are being developed as potential treatments for a range of conditions. Unlike CB1 agonists, CB2 agonists do not produce psychoactive effects and are generally well-tolerated. However, because CB2 activation can impact immune system function, these compounds need to be carefully evaluated for safety and efficacy.
In summary, Cannabinoid Receptor 2 (CB2) is a type of protein found on the surface of cells in the immune system and some other tissues. CB2 activation has potential therapeutic applications in conditions involving inflammation and immune system dysfunction, such as pain, multiple sclerosis, and inflammatory bowel disease. CB2 agonists do not produce psychoactive effects and are generally well-tolerated, but need to be carefully evaluated for safety and efficacy.
